Plain-English translation of NCT06173310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a special type of MRI scan called DCE-MRI can help doctors better understand how well chemotherapy is working for your pancreatic cancer. The scan measures blood flow in the tumor, which can show whether the treatment is effective or if a different approach might work better. This information could help your doctors decide whether to continue your current chemotherapy or try a different strategy to shrink the tumor enough for surgery.
Borderline-resectable pancreatic cancer is difficult to treat because the tumor is in a location where it's unclear whether surgery can safely remove it all. Doctors need better tools to know whether chemotherapy is actually shrinking the tumor and improving the chances of successful surgery. This new imaging technique may provide that clearer picture earlier in treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive chemotherapy as planned while also undergoing special MRI scans at certain points during your treatment. These DCE-MRI scans measure blood flow in your tumor to help your doctors understand whether the chemotherapy is working effectively. Based on what the scans show, your doctors can decide whether to continue your current chemotherapy or adjust your treatment plan before you move toward surgery.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States